140 related articles for article (PubMed ID: 16757022)
1. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
Steinhauser I; Spänkuch B; Strebhardt K; Langer K
Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
3. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles.
Kouchakzadeh H; Shojaosadati SA; Tahmasebi F; Shokri F
Int J Pharm; 2013 Apr; 447(1-2):62-9. PubMed ID: 23454849
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
Dinauer N; Balthasar S; Weber C; Kreuter J; Langer K; von Briesen H
Biomaterials; 2005 Oct; 26(29):5898-906. PubMed ID: 15949555
[TBL] [Abstract][Full Text] [Related]
5. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.
Steinhauser I; Langer K; Strebhardt K; Spänkuch B
J Drug Target; 2009 Sep; 17(8):627-37. PubMed ID: 19591537
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.
Taheri A; Dinarvand R; Atyabi F; Ghahremani MH; Ostad SN
Eur J Pharm Sci; 2012 Sep; 47(2):331-40. PubMed ID: 22771547
[TBL] [Abstract][Full Text] [Related]
7. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
[TBL] [Abstract][Full Text] [Related]
8. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine.
Chiu SJ; Ueno NT; Lee RJ
J Control Release; 2004 Jun; 97(2):357-69. PubMed ID: 15196762
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
12. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
13. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells.
Ulbrich K; Michaelis M; Rothweiler F; Knobloch T; Sithisarn P; Cinatl J; Kreuter J
Int J Pharm; 2011 Mar; 406(1-2):128-34. PubMed ID: 21185364
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
Recupero D; Daniele L; Marchiò C; Molinaro L; Castellano I; Cassoni P; Righi A; Montemurro F; Sismondi P; Biglia N; Viale G; Risio M; Sapino A
J Pathol; 2013 Feb; 229(3):390-9. PubMed ID: 22806884
[TBL] [Abstract][Full Text] [Related]
15. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.
Wartlick H; Michaelis K; Balthasar S; Strebhardt K; Kreuter J; Langer K
J Drug Target; 2004; 12(7):461-71. PubMed ID: 15621671
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.
Spänkuch B; Steinhauser I; Wartlick H; Kurunci-Csacsko E; Strebhardt KI; Langer K
Neoplasia; 2008 Mar; 10(3):223-34. PubMed ID: 18320067
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
19. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
20. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
Scollard DA; Chan C; Holloway CM; Reilly RM
Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
